USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
INVENIO THERAPEUTICS, INC.
Address:
1100 CEDAR AVE, STE 285
CLEVELAND, OH 44106-3007
Phone:
N/A
URL:
N/A
EIN:
156266652
DUNS:
801479333
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $270,690.00 2
SBIR Phase II $853,202.00 1

Award List:

Plant-derived differentiation agents for AML

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$142,460.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Plant-derived compounds, particularly alkaloids, have historically been a successful source of currently used therapeutics. Recently, a plant-derived alkaloid was identified that is a potent acute myeloid leukemia (AML) differentiation-inducing compound.… More

Novel differentiation therapy for AML

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$128,230.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Acute myeloid leukemia (AML) is one of the most common forms of leukemia in adults and despite advances in treatment the 5 year survival is less than 20-50% in adults and significantly lower in the elderly. The remarkab le success in treating one relatively… More

Natural product-derived differentiation agents for AML

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$853,202.00
Agency:
HHS
Principal Investigator:
Mukesh K. Agarwal – 216-496-9053
Abstract:
DESCRIPTION (provided by applicant): Though AML is one of the most common forms of leukemia in adults; the 5 year survival is less than 20-50% in adults and significantly lowers in the elderly. The remarkable success in treating one relatively uncommon subset of AML, acute promyelocytic leukemia… More